24th November 2006

ABC of a Health Problem: Antibiotics, Bacteria and Carriers

Evolution of typhoid bacteria

pie chart

In a study published in the latest issue of Science (24 November, 2006), an international consortium from the Max-Planck Society, Wellcome Trust Institutes in Britain and Viet Nam, and the Institut Pasteur in France have elucidated the evolutionary history of Salmonella Typhi.

Typhi is the cause of typhoid fever, a disease that affects 21 million people and kills 200,000 every year. The results indicate that asymptomatic carriers played an essential role in the evolution and global transmission of Typhi. One prediction from this rediscovery of the importance of the carrier state is that treatment of acute disease, including vaccination, is not enough to eradicate this disease.

" These methodologies will revolutionise the way we track certain pathogens (infectious agents) in the field "

Prof Gordon Dougan

The results also illuminate patterns leading to antibiotic resistance after the indiscriminate use of antibiotics. Fluoroquinolone treatment in southern Asia over two decades has resulted in the emergence of multiple, independent, nalidixic acid-resistant mutants, of which one group, H58, has multiplied dramatically and spread globally. Resistant strains reduce effectiveness of treatment using antibiotics. The report also has broad implications for analysing other emerging diseases.

Typhoid fever remains a major health problem in the developing world and continues to cause disease in Europe and the Americas. The evolutionary history and population structure of Typhi were poorly understood, partly because these bacteria show little genetic diversity.

Lack of information about the population structure of S. Typhi has impeded efforts to understand the epidemiology of the disease and to bring it under control in poorer countries. A project to solve this problem was derived through discussions between Mark Achtman from the Max-Planck Institut für Infektionsbiologie, Berlin and Gordon Dougan at the Wellcome Trust Sanger Institute and was underpinned by a large grant from the Wellcome Trust that also supported Philippe Roumagnac, a key scientist on this project.

The teams combined their resources to assemble for the first time a globally representative collection of 105 strains of Typhi, and investigated the sequence diversity within 90,000 base pairs per strain. They detected 88 informative sequence differences, showing that the population structure has evolved over the last 10,000 to 43,000 years.

Salmonella typhi

Amazingly, the ancestral strain continues to exist today, as do many of its direct descendents, indicating a neutral population structure, whereas normally selective forces lead to extinction of intermediate genotypes. Furthermore, these bacteria are distributed globally, demonstrating that Typhi has spread inter-continentally on multiple occasions.

The authors propose that the unusual population structure of Typhi reflects long-term carriage by asymptomatic carriers, who reached public notoriety at the beginning of the 20th century with "Mr. N the milker" in England and "Typhoid Mary" (Mary Mallon) in the USA. These individuals infected hundreds of people over the decades while they worked in the food production industry.

Similar, healthy carriers may have allowed Typhi to survive in hunter-gatherer populations prior to the Neolithic expansion of city states and facilitated its intercontinental spread. Healthy carriers are also consistent with the observation that individual genotypes of Typhi persist for many decades within each country.

Increasing resistance to antibiotics in recent decades has hampered efforts of clinicians to treat typhoid fever. The indiscriminate use of fluoroquinolones, which is a cost-effective, standard treatment for typhoid fever, has been accompanied by a frightening increase in the numbers of resistant Typhi. Investigations of a large strain collection from southern Asia revealed that many different genotypes independently acquired resistance to nalidixic acid, a fluoroquinolone. One of these genotypes, H58, has become predominant throughout southern Asia and has even spread to Africa.

In Viet Nam, up to 95% of Typhi are now resistant to nalidixic acid and many other antibiotics. Although these cases can still be treated with newer antibiotics, those antibiotics are much more expensive than standard fluoroquinolones, which raises the cost of medical treatment. Furthermore, it is likely that Typhi will develop resistance to these antibiotics as well.

The combination of these investigations raises problems for public health measures. Indiscriminate antibiotic usage results in real-time evolution of bacteria that resist treatment. Furthermore, the healthy carrier state provides a safe reservoir for these bacteria which allows them to evade short-term antibiotic treatment and vaccination, indicating that typhoid fever will remain a major health problem for the foreseeable future.

Notes to Editors

Publication details

  • Evolutionary history of Salmonella typhi.

    Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S, Chinh NT, Le TA, Acosta CJ, Farrar J, Dougan G and Achtman M

    Science (New York, N.Y.) 2006;314;5803;1301-4

Project information

The research was carried out collaboratively by the Max-Planck Institut für Infektionsbiologie in Berlin, the Wellcome Trust Sanger Institute, Hinxton Hall, the Institut Pasteur, Paris, and the Oxford University Clinical Research Unit, Ho Chi Minh City, with assistance from hospitals in Ho Chi Minh City and Hanoi and the International Vaccine Institute in Seoul.

Financial support was by the Wellcome Trust, UK.


The Wellcome Trust Sanger Institute

The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.


The Wellcome Trust and Its Founder

The Wellcome Trust is the most diverse biomedical research charity in the world, spending about £450 million every year both in the UK and internationally to support and promote research that will improve the health of humans and animals. The Trust was established under the will of Sir Henry Wellcome, and is funded from a private endowment, which is managed with long-term stability and growth in mind.


Sanger Institute Contact Information:

Don Powell Press Officer
Wellcome Trust Sanger Institute Hinxton, Cambs, CB10 1SA, UK

Tel +44 (0)1223 496 928
Mobile +44 (0)7753 7753 97
Fax +44 (0)1223 494 919
Email press.office@sanger.ac.uk

* quick link - http://q.sanger.ac.uk/m65ldwwv